The global left atrial appendage closure device market size was valued at USD 1.45 billion in 2023. It is estimated to reach USD 7.94 billion by 2032, growing at a CAGR of 20.74% during the forecast period (2024–2032).
Left atrial appendage closure (LAAC) is a procedure to seal off the left atrial appendage (LAA), a small sac in the left atrium, to reduce stroke risk in patients with atrial fibrillation (AF). AF causes chaotic heart contractions, leading to blood pooling and clot formation in the left atrial appendage. Closing or removing the left atrial appendage decreases the risk of stroke by eliminating the primary source of clots. This procedure is especially useful for patients who cannot tolerate or do not respond well to blood-thinning medications.
Factors such as the growing incidence of atrial fibrillation (AF) and increased awareness about stroke prevention are primary factors driving this left atrial appendage closure device market growth. Market expansion is also supported by advances in device technology, such as better safety profiles and more efficient use of instruments. In addition, the demand for left atrial appendage closure devices is increasing due to expanding reimbursement coverage and the growing elderly population, which is more susceptible to atrial fibrillation.
The rising incidence of atrial fibrillation, particularly among the aging population, is driving the demand for LAA closure devices. According to the CDC, more than 454,000 hospitalizations with AFib as the primary diagnosis happen each year in the US. The condition contributes to about 158,000 deaths each year. The death rate from AFib as the primary or a contributing cause of death has been rising for more than two decades.The rising incidence of atrial fibrillation, particularly among the aging population, significantly drives the demand for LAA closure devices. According to the CDC, more than 454,000 hospitalizations with AFib as the primary diagnosis happen each year in the US. With approximately 158,000 deaths each year. This results in rising demand for effective stroke prevention strategies such as advanced medical technologies “LAA closure devices”, in improving patient outcomes and reducing the burden on healthcare systems.
Technological Advancements
Innovations in Left Atrial Appendage (LAA) closure devices, particularly those focusing on minimally invasive procedures and enhanced safety profiles, have significantly improved patient outcomes and driven market adoption. These advancements have addressed key concerns related to traditional surgical approaches, offering more effective and safer alternatives for patients with atrial fibrillation (AF).
For instance, introduction of the WATCHMAN FLX Pro Left Atrial Appendage Closure Device by Boston Scientific features HEMOCOAT Technology, which promotes faster, more complete healing. It includes three radiopaque markers for 57% improved visibility, ensuring precise positioning and confident release. The device also comes in a new 40mm size to treat larger appendages while maintaining the same performance standards. These innovations make the WATCHMAN FLX Pro a leading choice for stroke prevention in atrial fibrillation patients. Thus, such innovations results in increasing the growth of the market.
The high cost of Left Atrial Appendage (LAA) closure devices and procedures is a significant restraint on their adoption, particularly in low- and middle-income countries. For instance, The National Library of Medicine reports that managing individual atrial fibrillation (AF) patients incurs substantial costs, ranging from USD 2000 to USD 14,200 per patient-year in the USA and €450 to €3000 in Europe. This overall cost of AF management presents a barrier for patients and healthcare systems, limiting access to LAA closure devices and procedures, thereby, hindering the widespread adoption of LAA closure as a stroke prevention strategy in AF patients.
Digital health solutions have emerged as promising tools for early detection of atrial fibrillation (AF) and prompt initiation of management. Countries should invest in existing cost-effective public health programs and clinical interventions to increase equitable access to digital devices, facilitating widespread AF screening and management.
The AF screening project in Taiwan is a prime example of government-endorsed initiatives to enhance public health outcomes. By integrating AF screening into existing health programs and ensuring coordinated efforts between public health systems and government bodies, the project achieved significant improvements in the detection and management of AF. This model can serve as a blueprint for similar initiatives worldwide, demonstrating the potential for government collaboration to enhance healthcare delivery and patient outcomes.
| Study Period | 2020-2032 | CAGR | 20.74% |
| Historical Period | 2020-2022 | Forecast Period | 2024-2032 |
| Base Year | 2023 | Base Year Market Size | USD 1.45 billion |
| Forecast Year | 2032 | Forecast Year Market Size | USD 7.94 billion |
| Largest Market | North America | Fastest Growing Market | Asia-Pacific |
Based on region, the global left atrial appendage closure device market share is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
North America is the most significant global left atrial appendage closure device market shareholder and is expected to expand substantially during the forecast period. North America stands as a prominent region in the global left atrial appendage closure device market, characterized by high prevalence of atrial fibrillation, well-established healthcare facilities and advanced medical technology, supporting the widespread adoption of innovative medical devices.
The United States left atrial appendage closure device industry is leading in terms of market share. The presence of major companies involved in production of the LAA closure devices such as Boston Scientific and Abbott, have a strong presence in country, contributing to the region's market leadership. Additionally, in the U.S., the Centers for Medicare & Medicaid Services (CMS) provide coverage for LAA closure devices, making them more accessible to patients and encouraging their use.
The Canadian market for left atrial appendage closure device is poised to grow due to technological innovations in the field of structural heart diseases by different players in the market in the ocuntry. For instance, the approval of the Amplatzer Steerable Delivery Sheath and Amulet LAA Occluder provides Canadian physicians with an advanced and innovative solution for managing stroke risk in patients with AF. This approval expands the treatment options available for patients who are unable to take long-term blood thinners, thereby, expanding the market growth.
Europe region is a pivotal market for the left atrial appendage closure devices. Atrial fibrillation (AF) is the most common heart rhythm disorder and is responsible for a significant proportion of healthcare spending in European countries. As per the, European Society of Cardiology, the estimated number of people suffering from AF are 7.6 million in 2016 and will increase upto 14.4 million by 2060, representing an 89% increase, resulting, in the rising demand for adequate treatment and devices such as left atrial appendage closure devices.
Germany left atrial appendage closure (LAAC) device market plays a significant role in influencing the dynamics of the Europe LAAC device market. This is evident from the substantial increase in the total number of LAAC procedures in Germany from 2016 to 2020, particularly with a notable rise in the utilization of endocardial occlusion devices. The increase in the number of centers offering endocardial LAA occlusion also contributed to this growth, driven by factors such as the aging population, increased awareness about LAAC, and advancements in technology.
France is also leading in left atrial appendage closure devices market due to prevalence of atrial fibrillation (AF) in France, with over 1 million people suffering from the condition and over 77,000 new diagnoses annually as per the European Medical Journal. Such rising numbers are indicating the need for effective treatment options such as left atrial appendage closure (LAAC) devices. These devices have the potential to improve patient outcomes, reduce healthcare costs, and alleviate the burden on the healthcare system.
Thus, the factors above are estimated to boost the Europe left atrial appendage closure device market growth.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The global left atrial appendage closure device market is segmented by product and end-use. Based on product, the global left atrial appendage closure device market is divided into Endocardial LAA Devices and Epicardial LAA Devices.
Endocardial LAA devices segment dominates the global market. Endocardial LAA devices are preferred due to their lower complication rates, shorter hospital stays, and fewer 30-day readmissions. Numerous clinical studies have demonstrated that endocardial LAA devices are safer and more effective in managing stroke and reducing bleeding compared to other options.
Moreover, the devices offers various benefits including ease of use and a robust product pipeline. Notable devices like the Watchman, which has received U.S. approval, and seven other devices with CE marks in Europe, contribute to this growth. These devices are currently undergoing clinical trials, further expanding the market.
Based on end-user, the global left atrial appendage closure device market is bifurcated into hospitals, ambulatory surgery centers, and others.
The hospital segment is estimated to own the market. Market players focus on promoting their products in hospitals through financial incentives and marketing strategies. For instance, Boston Scientific collaborated with MedAxiom and TogetherMD to offer value-based solutions in hospitals aimed at improving outcomes and reducing the cost of cardiovascular care delivery to healthcare systems..Hospitals adopt advanced medical technologies and have certified medical professionals, making them the preferred choice for LAAC procedures. For instance,Glenfield Hospital was one of the first to implant Boston Scientific’s WATCHMAN FLX LAAC device following its CE mark approval.
Thereby, the growth of the segment is driven by the increasing preference for LAA surgeries, the adoption of advanced LAAC devices, and the availability of cutting-edge medical technologies and skilled staff in hospitals.
As per our research analysts, Atrial fibrillation (AF) is a prevalent cardiac arrhythmia that significantly increases the risk of stroke and other cardiovascular complications, particularly in the aging population. The market for left atrial appendage closure (LAAC) devices is experiencing robust growth as these devices offer a viable alternative to long-term anticoagulation therapy, which poses bleeding risks. Key players like Boston Scientific and Abbott are driving innovation with advanced device designs and minimally invasive implantation techniques such as WATCHMAN and AMPLATZER Amulet LAA occluder respectively, supported by growing clinical evidence of their efficacy and safety. Despite the promising outlook, the market faces challenges such as stringent regulatory requirements, high costs, and reimbursement issues. The future of LAAC devices looks promising, with trends pointing towards personalized medicine, minimally invasive procedures, and integration with digital health technologies for remote patient monitoring. To capitalize on these opportunities, continuous improvements in device safety, efficacy, and ease of use, along with favorable regulatory and reimbursement landscapes, will be essential.
